Lantern Pharma (NASDAQ: LTRN) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering methods to select and treat patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The allowed claims focus on a three-gene biomarker signature—elevated expression of PTGR1, PTPN14, and ASPH—to identify patients who may benefit from LP-184 treatment.
The biomarker signature was identified using Lantern's proprietary RADR® artificial intelligence platform, which supports a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial. Lantern plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
This patent allowance underscores the potential of AI-driven biomarker discovery in oncology. By using a biomarker signature to pre-select patients, Lantern aims to improve treatment outcomes and reduce unnecessary side effects, aligning with the broader industry trend toward personalized medicine. For leaders in business and technology, this development highlights how artificial intelligence is being integrated into drug development to enhance efficiency and success rates.
Lantern's RADR platform, which includes its multi-agentic AI co-scientist platform withZeta.ai, is now commercially available as a subscription-based research tool for the global biomedical community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The patent follows Lantern's strategy of building a robust intellectual property portfolio around its AI-discovered biomarkers. For the pharmaceutical industry, this approach could serve as a model for leveraging AI to identify predictive biomarkers, potentially accelerating the development of targeted therapies. Investors and industry watchers should note that the success of LP-184 in upcoming trials could validate the use of AI in precision oncology, influencing future drug development strategies.
Lantern's clinical pipeline also includes LP-284, a TC-NER targeting compound for hematologic and solid tumors, and LP-300, a cisplatin/ethacraplatin analog being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
For more information, visit the company's newsroom at https://ibn.fm/LTRN.
